Showing 5541-5550 of 8624 results for "".
- Can IL-33 Blockade Ease Severe Poison Ivy Itch? Mouse Study Says Maybehttps://practicaldermatology.com/news/can-il-33-blockers-ease-severe-poison-ivy-itch/2458382/Blocking interleukin 33 (IL-33) may put the brakes on the uncontrollable itch caused by poison ivy, poison sumac, poison oak and even mango trees, according to a mouse study conducted by scientists at Duke Health in Durham, NC, and Zhejiang Chinese Medical University in China. The r
- FDA Approves Expanded Use Of Enbrel To Treat Children With Chronic Moderate-To-Severe Plaque Psoriasishttps://practicaldermatology.com/news/fda-approves-expanded-use-of-enbrel-to-treat-children-with-chronic-moderate-to-severe-plaque-psoriasis/2458383/The FDA has approved the supplemental Biologics License Application (sBLA) for the expanded use of Amgen's Enbrel (etanercept), making it the first and only systemic therapy to treat pediatric patients (ages 4-17) with chronic moderate-to-severe plaque psoriasis. The approval is based
- New Interim CEO Named For Canada's Crescitahttps://practicaldermatology.com/news/new-interim-ceo-for-canadas-crescita/2458386/Dan Chicoine is now the interim Chief Executive Officer of Crescita Therapeutics Inc., a commercial dermatology company in Canada. He is replacing Greg Orleski. Mr. Chicoine will also continue to serve as the Company's Executive
- Avon Chooses Greenwich, CT Dermatologist to Champion ANEW Brandhttps://practicaldermatology.com/news/avon-chooses-greenwich-conn-dermatologist-to-champion-anew-brand/2458390/Kim Nichols, MD, is now Avon’s new consulting dermatologist. In her role, the Greenwich, Conn.-based dermatologist will help to educate Avon Representatives on the technology behind the
- Brenton L. Saunders is Allergan's New Chairman of the Boardhttps://practicaldermatology.com/news/brenton-l-saunders-is-allergans-new-chairman-of-the-board/2458389/Brenton L. Saunders is Allergan’s new Chairman of the Board, the company reports. Effective today, Saunders will replace Paul Bisaro, who served as Executive Chairman since July 1, 2014. Bisaro will remain a member of the Allergan Board of
- Allergan Completes Vitae Tender Offerhttps://practicaldermatology.com/news/allergan-completes-vitae-tender-offer/2458391/Allergan completed their tender offer to purchase all outstanding shares of Vitae Pharmaceuticals, Inc., a clinical-stage biotechnology company. A tender offer occurs when
- Study Calls Attention to Negative Impact, Need for Treatment of SKhttps://practicaldermatology.com/news/study-calls-attention-to-negative-impact-need-for-treatment-of-sk/2458393/Patients with asymptomatic seborrheic keratosis (SK) are bothered by highly visible skin lesions and are very interested in treatment to improve their appearance, even if a cost were associated with treatment, according to a new study conducted in dermatology practices by Burke, Inc. on behalf of
- Pew Research Gauges Our Attitudes About Cosmetic Surgeryhttps://practicaldermatology.com/news/pew-research-gages-our-attitudes-about-cosmetic-surgery/2458395/New survey data from the Pew Research Center sheds light on American attitudes and beliefs regarding cosmetic surgery. The survey, conducted in
- Novan: Phase 2b Data for SB204 Gel to be Presented at Fall Clinical Dermatology Conferencehttps://practicaldermatology.com/news/novan-phase-2b-data-for-sb204-gel-to-be-presented-at-fall-clinical-dermatology-conference/2458396/Results from Novan’s Phase 2b clinical trial to evaluate the efficacy and safety of topical nitric oxide-releasing product candidate SB204 gel for the treatment of acne vulgaris will be presented at the 35th Anniversary Fall Clinical Dermatology Conference in Las Vegas. The presentation wil
- FDA Clears Merz Aesthetics' Cellfina System for Long-Term Improvement of Cellulitehttps://practicaldermatology.com/news/fda-clears-merz-aesthetics-cellfina-system-for-long-term-improvement-of-cellulite/2458399/The FDA has cleared the Cellfina System from Merz Aesthetics, a division of Merz North America, for the long-term improvement in the appearance of cellulite on the buttocks and thighs of adult females with no loss of benefit for up to 3 years. Cellfina is the only FDA-cleared minimally in